MindMed Invests $5 Million in NYU Langone for Psychedelic Research Center

Psychedelic medicine company MindMed is investing $5 million in a new research center. J.R Rahn, co-founder and co-CEO of MindMed, discusses the investment and plans to hit the markets.
We use cookies and similar technologies on this site to collect identifiers, such as IP address, and cookie and device IDs as described in our Privacy Policy.